Skip to content
DataLookout
Menu

GLAD-KENCT07852975

GLAD-KE GLioma Biomarker and Safety Assessment During Dietary Ketone Elevation Subtitle: A Surgical Biomarker Discovery Study of Ketogenic Therapy in Recurrent Glioma

StatusNot Yet Recruiting
PhaseNot applicable
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Primary completion pushed from Oct 15, 2029 to Nov 15, 2029
    • Start date pushed from Oct 15, 2026 to Nov 5, 2026
  2. Minor Secondary endpoints: 4 to 5
  3. Study First Submitted
  • Minor: routine updates

Endpoints

Primary

Feasibility as assessed by Proportion of patients who complete 80% or more of the study intervention
Timeframe: Enrollment, day 7 of diet intervention, immediately after surgery, and follow-up up to 30 days post intervention).
Safety as assessed by incidence and severity of treatment-associated adverse events
Timeframe: Enrollment, day 7 of diet intervention, immediately after surgery, follow-up up to 30 days post intervention

Secondary (5)

Proportion of patients achieving beta-hydroxybuterate (Analysis of metabolic marker BHB)
Change in beta-hydroxybuterate (BHB) on Magnetic Resonance Imaging with intervention
Change in beta-hydroxybuterate (BHB) on Spectroscopy (MRS)
Detection of Acetone (mL)
Time spent in ketosis

Arms and interventions

Ketone supplementExperimental

Patients will self-administer a ketone supplement 80 mg for 7 days leading up to the surgery

Ketone dietExperimental

Patients will follow a 2.5:1 - 3:1 ketogenic diet (KD) daily for 7 days leading up to the clinically indicated surgery.

Dietary supplements: Arm 1 will use Ketone supplement 80 gm daily

Other: Arm 2 will follow Ketogenic Diet 7 days leading up to the clinically indicated surgery.

Sites

1 site in 1 country

  • Oncology- BroadwayBaltimore, Maryland, United States